Celerion Selected To Support Biomarker Program Studies
Published on:
Applied Clinical Trials
Celerion announced it has been selected by the Foundation for the National Institutes of Health Biomarkers Consortium.
Celerion, an early stage clinical research services provider, announced it has been selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to provide clinical support for The Beta Cell Project. The Beta Cell Project is a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical recruitment and conduct to support The Beta Cell Project and assist the FNIH in developing pharmacodynamic measures of beta cell function, with the goal to create industry standards.
